ELVN · CIK 0001672619
What Enliven Therapeutics, Inc. told the SEC could break it.
Enliven's sharpest exposure is its China-centered supply chain: it relies on Pharmaron in China for preclinical and clinical services and active pharmaceutical ingredients (with additional API manufacturing in Europe), leaving it open to disruption from U.S.-China trade tensions — 2025-26 U.S. tariffs on Chinese-origin goods (despite some pharmaceutical exemptions), a Section 122 import surcharge, and FDA scrutiny of China contractors and data transfers. Underlying that, it is a clinical-stage biopharma that has never completed a clinical trial, has no approved products, and has never generated revenue, devoting nearly all resources to development. Looking ahead, any approved product would also face IRA Medicare price negotiation and inflation rebates.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- China tariffs / import surcharge & FDA China-contractor scrutinyhigh
2025-26 U.S. tariffs (fentanyl-related 10-20% and reciprocal 10-125% on Chinese-origin goods, plus a Section 122 import surcharge) and FDA scrutiny of China contractors/data transfers threaten Enliven's China-based supply, despite some pharmaceutical exemptions.
“between February 4, 2025 and February 24, 2026, the U.S. government imposed “fentanyl-related” tariffs of 10% to 20% on the import of almost all Chinese-origin items, as 70 well as an additional “reciprocal” tariff of 10% to 125% on certain products, with exemptions for certain pharmaceutical products and other specified items.”
SEC filing →As of 2026 - IRA Medicare drug-price negotiation & inflation rebatesmedium
The IRA lets the federal government negotiate maximum fair prices for certain single-source Medicare drugs and imposes inflation rebates, pressuring future pricing of Enliven's product candidates if approved.
“allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs”
Other disclosures
- clinical-stage; no approved products or revenuemedium
Enliven is a clinical-stage biopharma that has never completed a clinical trial, has no approved products and has never generated revenue, devoting substantially all resources to development.
“Former Enliven commenced operations in June 2019, has never completed a clinical trial, has no products approved for commercial sale and has never generated any revenue.”
SEC filing →As of 2026
Supplier concentration
- API/CRO supply from Pharmaron (China) and Europemedium
Enliven relies on Pharmaron in China for preclinical/clinical services and API supply (plus API manufacturing in Europe); these offshore, limited/sole-sourced inputs expose it to supply disruption from U.S.-China trade tensions.
“we use Pharmaron, located in China, to conduct preclinical studies and clinical trials and provide us with active pharmaceutical ingredients (“APIs”). Additionally, we manufacture APIs in Europe. Since these facilities are located outside of the United States, we are exposed to the possibility of product supply disru”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Pharmaron Beijing Co., Ltd.
“we use Pharmaron, located in China, to conduct preclinical studies and clinical trials and provide us with active pharmaceutical ingredients (“APIs”). Additionally, we manufacture APIs in Europe.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch